Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · IEX Real-Time Price · USD
24.73
+1.04 (4.37%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Dyne Therapeutics stock have an average target of 37.38, with a low estimate of 22 and a high estimate of 56. The average target predicts an increase of 51.15% from the current stock price of 24.73.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2024.
Analyst Ratings
The average analyst rating for DYN stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 5 | 5 |
| Buy | 2 | 2 | 2 | 1 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $47 | Buy | Reiterates | $47 | +90.05% | Mar 26, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $31 | Strong Buy | Maintains | $20 → $31 | +25.35% | Mar 8, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $33 → $37 | Strong Buy | Maintains | $33 → $37 | +49.62% | Mar 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +45.57% | Mar 6, 2024 |
| Stifel | Stifel | Strong Buy Maintains $35 → $41 | Strong Buy | Maintains | $35 → $41 | +65.79% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
27.09M
EPS This Year
-3.33
from -3.95
EPS Next Year
-3.31
from -3.33
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 110.3M | 224.2M | 252.3M | 607.1M |
| Avg | n/a | 27.1M | 113.5M | 129.9M | 391.3M |
| Low | n/a | n/a | 10.9M | n/a | 60.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 727.9% | 122.4% | 367.3% |
| Avg | - | - | 318.9% | 14.5% | 201.2% |
| Low | - | - | -59.8% | - | -53.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.96 | -2.30 | -1.12 | -1.00 | 0.62 |
| Avg | -3.33 | -3.31 | -2.77 | -1.60 | -0.47 |
| Low | -3.53 | -4.39 | -4.09 | -2.17 | -1.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.